If there's a changing of the guard in the Australian sharemarket this year where CSL overtakes Commonwealth Bank as the market's most valuable company, it'll be down to one factor.
Demand for CSL's core blood products went through the roof over the second half of 2019. Sales of its two core immunglobulin (IG) blood products named Hizentra and Privigen grew 37 per cent and 28 per cent respectively over the half year. A result Goldman Sachs described as stellar.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
